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Anti-tubercular agentsAbstract A series of thirty-six novel 5-(2-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl)acetyl)indolin-2-
one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin-2-one analogues were synthesized,
characterized and screened for their in vitro anti-tubercular activity against Mycobacterium
tuberculosis H37Rv strain. These compounds exhibited minimum inhibitory concentration between
1.56 and 50 lg/mL. Among these derivatives, compounds 10c, 10d, 10j, 10o and 10v (MIC 6.25
lg/mL) displayed moderate activity, while compounds 10e, 10l, 10q, 10w,10x, 12d, 12e and 12i
(MIC 3.12 lg/mL) showed good anti-tubercular activity and compounds 10f, 10k, 10p, 10r, 12f,
12j and 12k (MIC 1.56 lg/mL) exhibited excellent anti-tubercular activity. In addition, MTT assay
was accomplished on the active analogues of the series against mouse macrophage (RAW 264.7)
cells to evaluate the cytotoxic effect of the newly synthesized compounds and selectivity index of
the compounds was determined.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is a mortality disease caused by tubercle
bacilli. TB represents one of the major public health concerns
worldwide after the HIV/AIDS and it is one of the major causes
of death in HIV patients. In general, tubercle bacilli attack
every second individual according to the World Health
Organization (WHO). When Mycobacterium tuberculosiscetyl)in-
, http://
2 K.M. Naidu et al.(MTB) attacks lungs it leads to pulmonary TB and when MTB
assails to any part of the body such as kidney, spine and brain it
results in extra pulmonary TB. Majority of TB mortality cases
are evinced in the evolving countries and more than 50% of
deaths occur in Asia alone. According to WHO, in 2013 nine
million people fell ill with TB including 1.5 million people with
HIV among them. Worldwide, 0.51 million women died from
TB in 2013 and it is top three eradicators for women. In
2013, 0.55 million children fell ill with TB and assessed 0.08 mil-
lion children who were HIV-negative died from TB (WHO
Global TB report, 2014a, b). The Multidrug resistant TB
(MDR-TB) is a form of TB which occurs once MTB strain
turns resistant to the most effective anti-TB drugs i.e. isoniazid
and rifampin. In 2013, worldwide 0.45 million people devel-
oped MDR-TB and there were 0.21 million deaths resulting
from MDR-TB. Extensively drug resistant TB (XDR-TB)
occurs when MTB strain is resistant to at least isoniazid and
rifampin in addition to being resistant to one of the ﬂu-
oroquinolones, as well as resistant to at least one of the second
line injectable drugs i.e. amikacin, kanamycin or capreomycin.
By the end of 2013, XDR-TB was found worldwide in 100
countries. Approximately, 9% of MDR-TB cases lead to
XDR-TB which is associated with higher mortality rate than
MDR-TB. Totally drug resistant TB (TDR-TB) or extremely
drug resistant TB (XXDR-TB) is not been clearly deﬁned by
WHO. It transpires whenMTB strain becomes resistant to total
ﬁrst and second line anti-TB drugs. It is very uncontrollable
although not always difﬁcult to treat. Prevalence of XDR-TB
and TDR-TB has increased worldwide. While in last few dec-
ades there are no novel anti-TB drugs except for bedaquiline
and delamanid which are used for the treatment of pulmonary
MDR-TB patients in serious or life-threatening conditions
(WHO Global TB report, 2014a, b; Ashish et al., 2014).
Hence, there is an urgent need to explore for novel chemo-
phores which can cure drug resistant forms of this mortal dis-
ease with minimal side effects. Focus should also be to curtail
the cost of the drugs and the treatment era.
Heterocyclic derivatives have broad spectrum of biological
importance and applications. Chieﬂy, oxindole derivatives
have known pharmacological activities such as antimicrobial
(Singh et al., 2014), anticancer (Prathima et al., 2014;
Natarajan et al., 2004), antioxidant (Yasuda et al., 2013), ser-
ine palmitoyl transferase inhibitor (Kiser et al., 2012; Hanada,
2004), HIV protease inhibitors (Eissenstat et al., 2012), growth
hormone secretagogue (Tokunaga et al., 2005), progesterone
receptor antagonists (Fensome et al., 2002), neurodepressant
(Mannaioni et al., 1998), cyclin-dependent kinase inhibitor
(Woodard et al., 2003; Bramson et al., 2001), tyrosine kinase
inhibitor (Tourneau et al., 2007) and notably, few reports as
anti-tubercular agents (Ranjith Kumar et al., 2009; Gu¨zel
et al., 2008; Karali et al., 2007; Sriram et al., 2006; Chande
et al., 2005). Impressed by its wide range of pharmacological
activities and our continuous investigation on novel anti-TB
agents (Naidu et al., 2014) we envisaged to explore these new
analogues for anti-mycobacterial activity.
The benzisoxazole analogues have all-embracing biological
activities and physiochemical properties, viz. antimicrobial
(Suhas et al., 2011; Priya et al., 2005), anti-HIV (Deng et al.,
2009, 2006), antidiabetic (Shantharam et al., 2013), anticancer
(Monish and Chul-Hoon, 2003), antipsychotic (Chen et al.,
2013; Strupczewski et al., 1995), anticonvulsant (Malik et al.,
2014; Uno et al., 1979), and Acetylcholinesterase inhibitorsPlease cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
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5-tert-Butyl-N-pyrazol- 4-yl-4,5,6,7-tetrahydrobenzo[d]isoxa-
zole-3-carboxamide derivatives with excellent anti-TB activity
(Subash et al., 2008) and also our group recently published,
design, synthesis and antimycobacterial activity of various
3-(4-(substitutedsulfonyl)piperazin-1-yl) benzo[d]isoxazole
derivatives (Naidu et al., 2014).
The signiﬁcance of aryl piperazine, and lipophilicity of che-
mophores play vital role in the physiochemical properties and
biological activities. Attaching aryl piperazine analogues
enriches the lipophilicity of compounds (Mortenson et al.,
2011; Kakwani et al., 2011). Accordingly, aryl piperazine
derivatives are known to exhibit wide range of pharmacologi-
cal activities and physiochemical properties. Indeed, these
aryl piperazine analogues display enhanced antibacterial and
anti-TB activity (Patel et al., 2014; Nagesh et al., 2014;
Thomas et al., 2011; Punkvang et al., 2010; Tangallapally
et al., 2005).
Enthused by the pharmacological activities and signiﬁcance
of oxindole, benzisoxazole and aryl piperazine motifs, we
sketched out a synthetic route to incorporate these three
pharmacophores into a single framework. We designed and
synthesized new 5-(2-(4-(benzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)indolin-2-one and 5-(2-(4-substitutedpiperazin-1-
yl)acetyl)indolin-2-one analogues and evaluated for their
antimycobacterial activity. The strategy to achieve title com-
pounds is portrayed in Fig. 1.
2. Material and methods
2.1. General
Chemicals and solvents were procured from commercial units,
viz. Aldrich India Ltd., E. Merck India Ltd. These solvents
and reagents were of LR grade and if necessary puriﬁed before
use. Thin-layer chromatography (TLC) was carried out on alu-
minium-supported silica gel plates (Merck 60 F254) with
visualization of components by UV light (254 nm). Column
chromatography was carried out on silica gel (Merck 100–
200 mesh). 1H NMR spectra and 13C NMR spectra were
recorded at 400 MHz using a Bruker AV 400 spectrometer
(Bruker CO., Switzerland) in CDCl3 and DMSO-d6 solution
with tetramethylsilane as the internal standard, and chemical
shift values (d) were given in ppm. Title compound reactions
are accomplished in Biotage Microwave Synthesizer (model –
Initiator 2.5). Melting points were determined on an elec-
trothermal melting point apparatus (Stuart-SMP30) in open
capillary tubes and are uncorrected. IR spectra were recorded
with an FT-IR spectrophotometer (Jasco FTIR-4200). Solid
compounds were analysed by KBr disc method and semi-solid
compounds were recorded as neat samples. mmax is expressed in
cm1; Elemental analyses were analysed by Elementar
Analysensysteme GmbH vario MICRO cube CHNS/O
Analyzer. Mass spectra (ESI–MS) were recorded on
Schimadzu MS/ESI mass spectrometer. All tested compounds’
purity was greater than 95%.
2.2. Experimental
We synthesized key intermediates, substituted 5-(2-
chloroacetyl)indolin-2-ones (4a–f), from N-substituted anilinesevaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
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Figure 1 Design strategy to achieve title compounds.
Design, synthesis and biological evaluation 3(1a–c) as per literature protocol (Howard et al., 1996; Sumpter
et al., 1945). On other hand, cardinal synthon 3-(piperazin-1-
yl)benzo[d]isoxazole derivatives (9a–d) were prepared from sub-
stituted 2-chlorobenzaldehyde (5a–d) according to our recently
published article (Naidu et al., 2014).
2.2.1. General procedure for the synthesis of 5-(2-(4-
(benzo[d]isoxazol-3-yl)piperazin-1-yl)acetyl)indolin-2-one
(10a–x) and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin-
2-one (12a–l) derivatives:
To a mixture of 3-(piperazin-1-yl)benzo[d]isoxazole derivatives
(9a–d) (1.0 equiv.) or 4-substitutedpiperazin (11a–b) (1.0
equiv.) analogues, oxindole derivatives (4a–f) (1.1 equiv.) and
anhydrous potassium carbonate (1.2 equiv.) were added in ace-
tonitrile and reﬂuxed in microwave oven for 10 min. Once the
reaction is complete, as indicated by TLC, the reaction mixture
was allowed to rt. The reaction mixture was quenched with
water and extracted with CH2Cl2. The organic layers were col-
lected, washed with saturated brine solution, dried over anhy-
drous Na2SO4 and concentrated in vacuo. The resultant crude
products were puriﬁed by column chromatography (1–8%
methanol in CH2Cl2) to get the title compounds in yields rang-
ing from 60% to 94%.
2.2.1.1. 5-(2-(4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl)acetyl)
indolin-2-one (10a). Appearance: pale orange solid;
mp = 164–165 C; FTIR: 3366, 3174, 3037, 1726, 1681,
1522, 1500, 1446, 908. 1H NMR (400 MHz, DMSO-d6) d
8.92 (b, 1H), 8.08 (d, J= 9.6 Hz, 1H), 7.96 (s, 1H), 7.70 (d,
J= 8.4 Hz, 1H), 7.48 (m, 2H), 7.24 (dd, J= 8.0 Hz, 1H),
6.89 (dd, J= 8.0 Hz, 1H), 3.88 (s, 2H), 3.69 (t, 4H), 3.57 (s,
2H), 2.80 (t, 4H). 13C NMR (100 MHz, DMSO-d6) d 190.81,
178.78, 163.31, 160.08, 148.56, 131.22, 130.45, 129.94, 127.89,
123.41, 122.97, 122.75, 115.12, 110.28, 108.44, 63.23, 52.98,
44.34, 34.12. ESI–MS: (m/z) calculated for C21H20N4O3,Please cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
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C21H20N4O3: (%) C 67.01, H 5.36, N 14.88. Found: C 67.12,
H 5.41, N 14.94.2.2.1.2. 5-(2-(4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl)ace-
tyl)-3-methylindolin-2-one (10b). Appearance: pale yellow
semi solid; mp = not determined (ND); FTIR: 3385, 3156,
3061, 1721, 1699, 1550, 1502, 1451, 920. 1H NMR
(400 MHz, DMSO-d6) d 8.81 (b, 1H), 8.04 (d, J= 9.6 Hz,
1H), 7.91 (s, 1H), 7.74 (d, J= 8.4 Hz, 1H), 7.52 (m, 2H),
7.25 (dd, J= 8.0 Hz, 1H), 6.92 (dd, J= 8.0 Hz, 1H), 3.87
(s, 2H), 3.65 (t, 4H), 3.48 (q, 1H), 2.92 (t, 4H), 1.51 (d,
J= 7.2 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) d 191.02,
178.94, 162.75, 161.12, 149.03, 132.11, 130.29, 129.88, 127.45,
124.12, 123.94, 122.67, 116.23, 111.35, 107.98, 64.01, 53.11,
43.89, 41.56, 15.78. ESI–MS: (m/z) calculated for
C22H22N4O3, calculated: 390.16, found: 391.24 (M+ H)
+.
Anal. Calcd for C22H22N4O3: (%) C 67.68, H 5.68, N 14.35.
Found: C 67.76, H 5.74, N 14.42.2.2.1.3. 5-(2-(4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl)ace-
tyl)-1-methylindolin-2-one (10c). Appearance: pale yellow
solid; mp = 178–179 C; FTIR: 3098, 3042, 1718, 1700,
1548, 1499, 1438, 918. 1H NMR (400 MHz, CDCl3) d 8.08
(d, J= 9.6 Hz, 1H), 7.95 (s, 1H), 7.70 (d, J= 8.4 Hz, 1H),
7.51 (m, 2H), 7.24 (dd, J= 8.0 Hz, 1H), 6.89 (dd,
J= 8.0 Hz, 1H), 3.86 (s, 2H), 3.67 (t, 4H), 3.58 (s, 2H), 3.26
(s, 3H), 2.83 (t, 4H). 13C NMR (100 MHz, CDCl3) d 192.01,
179.27, 162.68, 161.11, 149.84, 130.86, 130.09, 129.66, 128.22,
124.57, 123.34, 122.79, 117.14, 116.68, 110.24, 63.55, 52.61,
43.94, 36.33, 34.28. ESI–MS: (m/z) calculated for
C22H22N4O3, calculated: 390.16, found: 391.26 (M+ H)
+.
Anal. Calcd for C22H22N4O3: (%) C 67.68, H 5.68, N 14.35.
Found: C 67.78, H 5.72, N 14.46.evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
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tyl)-1,3-dimethylindolin-2-one (10d). Appearance: brown
solid; mp = 114–115 C; FTIR: 3148, 3068, 1722, 1698,
1544, 1502, 1446, 915. 1H NMR (400 MHz, CDCl3) d 8.10
(d, J= 9.6 Hz, 1H), 7.94 (s, 1H), 7.67 (d, J= 8.4 Hz, 1H),
7.49 (m, 2H), 7.23 (dd, J= 8.0 Hz, 1H), 6.95 (dd,
J= 8.0 Hz, 1H), 3.92 (s, 2H), 3.68 (t, 4H), 3.52 (q, 1H), 3.27
(s, 3H), 2.88 (t, 4H), 1.48 (d, J= 6.8 Hz, 3H). 13C NMR
(100 MHz, CDCl3) d 191.48, 178.74, 163.08, 160.89, 149.57,
131.80, 130.22, 129.01, 128.31, 124.38, 123.12, 122.04, 118.22,
117.21, 110.99, 63.65, 53.01, 44.23, 41.28, 37.64, 16.25. ESI–
MS: (m/z) calculated for C23H24N4O3, calculated: 404.18,
found: 405.23 (M+H)+. Anal. Calcd for C23H24N4O3: (%)
C 68.30, H 5.98, N 13.85. Found: C 68.41, H 5.92, N 13.94.
2.2.1.5. 5-(2-(4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl)ace-
tyl)-1-ethylindolin-2-one (10e). Appearance: pale yellow solid;
mp = 174–175 C; FTIR: 3154, 3068, 1720, 1688, 1549, 1500,
1451, 921. 1H NMR (400 MHz, CDCl3) d 8.06 (d, J= 8.6 Hz,
1H), 7.92 (s, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.50 (m, 2H), 7.24
(dd, J= 8.0 Hz, 1H), 6.96 (dd, J= 8.0 Hz, 1H), 3.90 (s, 2H),
3.66 (t, 4H), 3.54 (s, 2H), 3.31 (q, 2H), 2.92 (t, 4H), 1.31 (t,
3H). 13C NMR (100 MHz, CDCl3) d 190.98, 178.11, 163.75,
161.02, 148.24, 131.77, 130.45, 130.11, 128.88, 124.65, 123.13,
122.40, 117.02, 116.27, 109.44, 61.02, 52.13, 44.52, 40.56,
36.04, 13.18. ESI–MS: (m/z) calculated for C23H24N4O3, calcu-
lated: 404.18, found: 405.26 (M+H)+. Anal. Calcd for
C23H24N4O3: (%) C 68.30, H 5.98, N 13.85. Found: C 68.43,
H 5.94, N 13.91.2.2.1.6. 5-(2-(4-(Benzo[d]isoxazol-3-yl)piperazin-1-yl)ace-
tyl)-1-ethyl-3-methylindolin-2-one (10f). Appearance: orange
solid; mp = 120–121 C; FTIR: 3160, 3075, 1714, 1692,
1547, 1508, 1450, 924. 1H NMR (400 MHz, CDCl3) d 8.07
(d, J= 8.4 Hz, 1H), 7.94 (s, 1H), 7.70 (d, J= 8.0 Hz, 1H),
7.51 (m, 2H), 7.24 (dd, J= 8.0 Hz, 1H), 6.91 (dd,
J= 8.4 Hz, 1H), 3.87 (s, 2H), 3.81 (q, 2H), 3.68 (t, 4H), 3.50
(q, 1H), 2.84 (t, 4H), 1.52 (d, J= 7.6 Hz, 3H), 1.30 (t, 3H).
13C NMR (100 MHz, CDCl3) d 189.83, 177.84, 163.30,
160.09, 148.54, 131.12, 130.32, 129.91, 127.89, 123.40, 122.97,
122.80, 115.11, 110.18, 108.30, 59.75, 51.09, 44.34, 40.12,
34.19, 14.78, 12.55. ESI–MS: (m/z) calculated for
C24H26N4O3, calculated: 418.20, found: 419.28 (M+ H)
+.
Anal. Calcd for C24H26N4O3: (%) C 68.88, H 6.26, N 13.39.
Found: C 68.94, H 6.12, N 13.42.2.2.1.7. 5-(2-(4-(4-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)indolin-2-one (10g). Appearance: Pale yellow semi
solid; mp = ND; FTIR: 3381, 3165, 3038, 1721, 1688, 1519,
1501, 1446, 900, 780. 1H NMR (400 MHz, DMSO-d6) d 8.68
(b, 1H), 8.00 (d, J= 8.4 Hz, 1H), 7.90 (s, 1H), 7.72 (dd,
J= 1.2 Hz, 1H), 7.68 (m, 1H), 7.49 (dd, J= 0.8 Hz, 1H),
7.28 (dd, J= 8.4 Hz, 1H), 3.91 (s, 2H), 3.72 (t, 4H), 3.48 (s,
2H), 2.81 (t, 4H). 13C NMR (100 MHz, DMSO-d6) d 190.76,
179.08, 163.45, 161.11, 149.03, 132.33, 131.48, 130.92, 129.89,
129.47, 123.97, 122.75, 118.12, 111.35, 109.87, 63.11, 52.91,
44.13, 34.83. ESI–MS: (m/z) calculated for C21H19ClN4O3, cal-
culated: 410.11, found: 411.18 (M+H)+. Anal. Calcd for
C21H19ClN4O3: (%) C 61.39, H 4.66, N 13.64. Found: C
61.47, H 4.72, N 13.72.Please cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
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yl)acetyl)-3-methylindolin-2-one (10h). Appearance: pale yel-
low solid; mp = 149–150 C; FTIR: 3368, 3164, 3030, 1718,
1679, 1518, 1508, 1451, 902, 788. 1H NMR (400 MHz,
DMSO-d6) d 8.71 (b, 1H), 8.01 (d, J= 8.4 Hz, 1H), 7.91 (s,
1H), 7.74 (dd, J= 1.2 Hz, 1H), 7.68 (m, 1H), 7.47 (dd,
J= 0.8 Hz, 1H), 7.29 (d, J= 8.4 Hz, 1H), 3.93 (s, 2H), 3.67
(t, 4H), 3.60 (q, 1H), 2.62 (t, 4H), 1.53 (d, J= 7.2 Hz, 3H).
13C NMR (100 MHz, DMSO-d6) d 191.08, 179.12, 162.23,
160.92, 149.45, 132.02, 131.27, 130.66, 129.47, 129.11, 124.14,
123.23, 120.04, 112.35, 111.05, 64.01, 52.44, 43.84, 40.88,
35.12, 16.13. ESI–MS: (m/z) calculated for C22H21ClN4O3, cal-
culated: 424.13, found: 425.22 (M+H)+. Anal. Calcd for
C22H21ClN4O3: (%) C 62.19, H 4.98, N 13.19. Found: C
62.27, H 5.03, N 13.26.
2.2.1.9. 5-(2-(4-(4-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-methylindolin-2-one (10i). Appearance: pale yel-
low solid; mp = 191–192 C; FTIR: 3179, 3048, 1717, 1670,
1512, 1508, 1450, 895, 792. 1H NMR (400 MHz, CDCl3) d
8.07 (d, J= 8.4 Hz, 1H), 7.90 (s, 1H), 7.71 (dd, J= 1.6 Hz,
1H), 7.58 (m, 1H), 7.46 (dd, J= 1.2 Hz, 1H), 7.28 (d,
J= 7.6 Hz, 1H), 3.88 (s, 2H), 3.69 (t, 4H), 3.63 (s, 2H), 3.34
(s, 3H), 2.81 (t, 4H). 13C NMR (100 MHz, CDCl3) d 190.71,
177.84, 163.03, 160.57, 150.12, 132.24, 131.11, 130.26, 129.86,
129.01, 124.38, 123.09, 119.84, 116.91, 110.12, 63.87, 52.22,
43.07, 35.19, 33.82. ESI–MS: (m/z) calculated for
C22H21ClN4O3, calculated: 424.13, found: 425.25 (M+H)
+.
Anal. Calcd for C22H21ClN4O3: (%) C 62.19, H 4.98, N
13.19. Found: C 62.23, H 5.05, N 13.24.
2.2.1.10. 5-(2-(4-(4-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1,3-dimethylindolin-2-one (10j). Appearance: pale
yellow solid; mp = 209–210 C; FTIR: 3182, 3045, 1723,
1663, 1534, 1500, 1458, 898, 799. 1H NMR (400 MHz,
CDCl3) d 8.08 (d, J= 8.8 Hz, 1H), 7.91 (s, 1H), 7.71 (dd,
J= 1.2 Hz, 1H), 7.65 (m, 1H), 7.46 (dd, J= 1.6 Hz, 1H),
7.27 (d, J= 8.4 Hz, 1H), 3.92 (s, 2H), 3.68 (t, 4H), 3.51 (q,
1H), 3.29 (s, 3H), 2.92 (t, 4H), 1.54 (d, J= 6.0 Hz, 3H). 13C
NMR (100 MHz, CDCl3) d 191.23, 178.18, 163.24, 159.11,
150.20, 132.21, 131.01, 130.67, 129.45, 129.23, 124.18, 123.31,
119.89, 116.78, 110.54, 63.18, 52.12, 43.11, 41.19, 35.24,
15.69. ESI–MS: (m/z) calculated for C23H23ClN4O3, calcu-
lated: 438.14, found: 439.28 (M+H)+. Anal. Calcd for
C23H23ClN4O3: (%) C 62.94, H 5.28, N 12.77. Found: C
63.02, H 5.33, N 12.84.
2.2.1.11. 5-(2-(4-(4-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-ethylindolin-2-one (10k). Appearance: pale brown
solid; mp = 188–189 C; FTIR: 3180, 3048, 1720, 1651, 1534,
1498, 1461, 899, 801. 1H NMR (400 MHz, CDCl3) d 8.00 (d,
J= 8.4 Hz, 1H), 7.90 (s, 1H), 7.72 (dd, J= 1.2 Hz, 1H),
7.68 (m, 1H), 7.48 (dd, J= 1.2 Hz, 1H), 7.28 (d, J= 8.4 Hz,
1H), 3.91 (s, 2H), 3.80 (q, 2H), 3.69 (s, 2H), 3.46 (t, 4H),
2.51 (t, 4H), 1.18 (t, 3H). 13C NMR (100 MHz, CDCl3) d
190.74, 178.79, 163.46, 160.23, 149.53, 132.04, 131.66, 130.23,
129.12, 129.00, 124.21, 123.22, 118.17, 115.78, 110.28, 63.89,
52.56, 43.09, 40.78, 36.00, 16.21. ESI–MS: (m/z) calculated
for C23H23ClN4O3, calculated: 438.14, found: 439.22
(M+ H)+. Anal. Calcd for C23H23ClN4O3: (%) C 62.94, H
5.28, N 12.77. Found: C 63.00, H 5.35, N 12.82.evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
Design, synthesis and biological evaluation 52.2.1.12. 5-(2-(4-(4-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-ethyl-3-methylindolin-2-one (10l). Appearance:
pale yellow solid; mp = 158–159 C; FTIR: 3179, 3049,
1720, 1656, 1555, 1503, 1450, 896, 800. 1H NMR (400 MHz,
CDCl3) d 8.09 (d, J= 8.4 Hz, 1H), 7.91 (s, 1H), 7.74 (dd,
J= 1.6 Hz, 1H), 7.70 (m, 1H), 7.47 (dd, J= 8.0 Hz, 1H),
7.32 (d, J= 7.6 Hz, 1H), 3.98 (s, 2H), 3.82 (q, 2H), 3.76 (t,
4H), 3.61 (q, 1H), 2.94 (t, 4H), 1.52 (d, J= 7.2 Hz, 3H),
1.24 (t, 3H). 13C NMR (100 MHz, CDCl3) d 191.08, 178.65,
163.63, 160.37, 149.77, 132.11, 131.28, 130.45, 129.11, 129.47,
124.04, 123.25, 118.28, 116.09, 110.24, 63.17, 52.62, 43.45,
41.18, 39.79, 16.24, 14.92. ESI–MS: (m/z) calculated for
C24H25ClN4O3, calculated: 452.16, found: 453.22 (M+ H)
+.
Anal. Calcd for C24H25ClN4O3: (%) C 63.64, H 5.56, N
12.37. Found: C 63.71, H 5.59, N 12.42.
2.2.1.13. 5-(2-(4-(6-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)indolin-2-one (10m). Appearance: pale yellow semi
solid; mp = ND; FTIR: 3402, 3188, 3062, 1718, 1650, 1552,
1508, 1451, 897, 811. 1H NMR (400 MHz, DMSO-d6) d 8.98
(b, 1H), 7.98 (d, J= 8.0 Hz, 1H), 7.92 (d, J= 8.4 Hz, 1H),
7.67 (s, 1H), 7.57 (d, J= 8.8 Hz, 1H), 7.50 (d, J= 8.4 Hz,
1H), 7.34 (s, 1H), 3.90 (s, 2H), 3.76 (t, 4H), 3.41 (s, 2H),
2.84 (t, 4H). 13C NMR (100 MHz, DMSO-d6) d 190.81,
179.84, 163.12, 160.25, 149.76, 135.08, 131.75, 130.24, 129.39,
124.14, 123.88, 122.72, 118.02, 110.95, 109.27, 63.23, 52.57,
43.28, 33.89. ESI–MS: (m/z) calculated for C21H19ClN4O3, cal-
culated: 410.11, found: 411.22 (M+ H)+. Anal. Calcd for
C21H19ClN4O3: (%) C 61.39, H 4.66, N 13.64. Found: C
61.45, H 4.75, N 13.69.
2.2.1.14. 5-(2-(4-(6-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-3-methylindolin-2-one (10n). Appearance: pale yel-
low solid; mp = 129–131 C; FTIR: 3398, 3182, 3053, 1716,
1650, 1551, 1502, 1459, 912, 804. 1H NMR (400 MHz,
DMSO-d6) d 8.81 (b, 1H), 8.02 (d, J= 8.0 Hz, 1H), 7.94 (d,
J= 8.4 Hz, 1H), 7.69 (s, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.51
(d, J= 8.0 Hz, 1H), 7.32 (s, 1H), 3.86 (s, 2H), 3.68 (t, 4H),
3.54 (q, 1H), 2.68 (t, 4H), 1.44 (d, J= 7.2 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) d 190.94, 179.82, 163.59,
160.01, 149.76, 136.11, 131.45, 130.07, 129.21, 124.02, 123.48,
122.63, 118.58, 111.23, 108.98, 63.44, 53.02, 43.74, 39.98,
14.12. ESI–MS: (m/z) calculated for C22H21ClN4O3, calcu-
lated: 424.13, found: 425.20 (M+ H)+. Anal. Calcd for
C22H21ClN4O3: (%) C 62.19, H 4.98, N 13.19. Found: C
62.26, H 5.01, N 13.24.
2.2.1.15. 5-(2-(4-(6-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-methylindolin-2-one (10o). Appearance: pale yel-
low solid; mp = 177–179 C; FTIR: 3168, 3044, 1718, 1668,
1550, 1501, 1454, 906, 810. 1H NMR (400 MHz, CDCl3) d
8.08 (d, J= 8.4 Hz, 1H), 7.91 (d, J= 8.4 Hz, 1H), 7.52 (d,
J= 8.0 Hz, 1H), 7.48 (d, J= 8.0 Hz, 1H), 7.31 (s, 1H), 7.29
(s, 1H), 3.84 (s, 2H), 3.68 (t, 4H), 3.60 (s, 2H), 3.37 (s, 3H),
2.72 (t, 4H). 13C NMR (100 MHz, CDCl3) d 191.35, 177.79,
163.24, 160.22, 149.88, 135.72, 130.91, 130.11, 129.23, 124.00,
123.57, 122.52, 119.40, 115.24, 112.64, 63.23, 53.11, 44.24,
34.92, 34.08. ESI–MS: (m/z) calculated for C22H21ClN4O3, cal-
culated: 424.13, found: 425.25 (M+ H)+. Anal. Calcd for
C22H21ClN4O3: (%) C 62.19, H 4.98, N 13.19. Found: C
62.23, H 5.05, N 13.24.Please cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
dolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin -2-one analogues a
dx.doi.org/10.1016/j.arabjc.2015.02.0252.2.1.16. 5-(2-(4-(6-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1,3-dimethylindolin-2-one (10p). Appearance: pale
brown solid; mp = 99–101 C; FTIR: 3167, 3048, 1721,
1650, 1548, 1500, 1452, 902, 811. 1H NMR (400 MHz,
CDCl3) d 8.10 (d, J= 8.8 Hz, 1H), 8.02 (d, J= 9.2 Hz, 1H),
7.55 (d, J= 8.4 Hz, 1H), 7.96 (d, J= 8.4 Hz, 1H), 7.43 (s,
1H), 7.23 (s, 1H), 3.87 (s, 2H), 3.69 (t, 4H), 3.54 (q, 1H),
3.28 (s, 3H), 2.82 (t, 4H), 1.48 (d, J= 6.8 Hz, 3H). 13C
NMR (100 MHz, CDCl3) d 192.08, 178.48, 163.82, 160.43,
149.89, 134.85, 130.76, 130.22, 129.34, 124.38, 123.21, 122.78,
118.35, 116.14, 111.83, 63.86, 53.24, 43.65, 40.68, 38.54,
16.18. ESI–MS: (m/z) calculated for C23H23ClN4O3, calcu-
lated: 438.14, found: 439.24 (M+H)+. Anal. Calcd for
C23H23ClN4O3: (%) C 62.94, H 5.28, N 12.77. Found: C
63.07, H 5.31, N 12.86.
2.2.1.17. 5-(2-(4-(6-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-ethylindolin-2-one (10q). Appearance: pale brown
solid; mp = 169–171 C; FTIR: 3172, 3054, 1720, 1649, 1547,
1498, 1450, 900, 818. 1H NMR (400 MHz, CDCl3) d 8.11 (d,
J= 8.8 Hz, 1H), 8.00 (d, J= 9.6 Hz, 1H), 7.90 (d,
J= 7.6 Hz, 1H), 7.88 (d, J= 8.0 Hz, 1H), 7.43 (s, 1H), 7.28
(s, 1H), 4.11 (s, 2H), 3.78 (q, 2H), 3.69 (s, 2H), 3.38 (t, 4H),
2.51 (t, 4H), 1.18 (t, 3H). 13C NMR (100 MHz, CDCl3) d
192.14, 178.23, 163.67, 160.52, 149.95, 135.12, 131.47, 130.04,
129.28, 124.21, 123.63, 122.09, 118.85, 116.67, 111.69, 63.45,
53.32, 43.88, 40.11, 35.23, 15.02. ESI–MS: (m/z) calculated
for C23H23ClN4O3, calculated: 438.14, found: 439.26
(M+H)+. Anal. Calcd for C23H23ClN4O3: (%) C 62.94, H
5.28, N 12.77. Found: C 63.03, H 5.34, N 12.84.
2.2.1.18. 5-(2-(4-(6-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-ethyl-3-methylindolin-2-one (10r). Appearance:
pale brown solid; mp = 122–123 C; FTIR: 3170, 3060,
1724, 1651, 1555, 1499, 1452, 909, 812. 1H NMR (400 MHz,
CDCl3) d 8.08 (d, J= 8.4 Hz, 1H), 7.94 (d, J= 9.2 Hz, 1H),
7.88 (d, J= 8.0 Hz, 1H), 7.81 (d, J= 8.0 Hz, 1H), 7.40 (s,
1H), 7.31 (s, 1H), 3.92 (s, 2H), 3.81 (q, 2H), 3.79 (t, 4H),
3.57 (q, 1H), 2.85 (t, 4H), 1.25 (d, J= 6.0 Hz, 3H), 1.24 (t,
3H). 13C NMR (100 MHz, CDCl3) d 191.74, 178.65, 163.23,
160.11, 149.84, 135.31, 131.68, 130.35, 129.69, 124.11, 123.64,
122.54, 118.63, 116.98, 111.84, 63.40, 53.12, 44.08, 40.74,
39.82, 16.45, 14.87. ESI–MS: (m/z) calculated for
C24H25ClN4O3, calculated: 452.16, found: 453.24 (M+ H)
+.
Anal. Calcd for C24H25ClN4O3: (%) C 63.64, H 5.56, N
12.37. Found: C 63.70, H 5.62, N 12.46.
2.2.1.19. 5-(2-(4-(7-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)indolin-2-one (10s). Appearance: pale yellow semi
solid; mp = ND; FTIR: 3398, 3168, 3058, 1721, 1652, 1550,
1498, 1455, 902, 818. 1H NMR (400 MHz, DMSO-d6) d 9.12
(b, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.91 (d, J= 8.0 Hz, 1H),
7.77 (s, 1H), 7.54 (d, J= 7.6 Hz, 1H), 7.47 (d, J= 8.4 Hz,
1H), 7.30 (m, 1H), 3.88 (s, 2H), 3.76 (t, 4H), 3.50 (s, 2H),
2.65 (t, 4H). 13C NMR (100 MHz, DMSO-d6) d 191.97,
179.82, 161.12, 159.45, 148.92, 131.75, 130.46, 129.34, 127.88,
123.45, 122.29, 122.46, 119.92, 116.28, 109.48, 63.21, 52.98,
44.34, 34.36. ESI–MS: (m/z) calculated for C21H19ClN4O3, cal-
culated: 410.11, found: 411.22 (M+ H)+. Anal. Calcd for
C21H19ClN4O3: (%) C 61.39, H 4.66, N 13.64. Found: C
61.45, H 4.71, N 13.74.evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
6 K.M. Naidu et al.2.2.1.20. 5-(2-(4-(7-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-3-methylindolin-2-one (10t). Appearance: pale yel-
low solid; mp = 168–170 C; FTIR: 3405, 3172, 3063, 1720,
1658, 1557, 1500, 1464, 908, 821. 1H NMR (400 MHz,
DMSO-d6) d 9.08 (b, 1H), 8.05 (d, J= 8.8 Hz, 1H), 7.90 (d,
J= 8.0 Hz, 1H), 7.68 (s, 1H), 7.49 (d, J= 8.4 Hz, 1H), 7.29
(d, J= 8.4 Hz, 1H), 7.32 (m, 1H), 3.91 (s, 2H), 3.70 (t, 4H),
3.68 (q, 1H), 2.65 (t, 4H), 1.25 (d, J= 6.4 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) d 191.82, 179.85, 161.31,
159.87, 148.90, 131.98, 130.33, 129.28, 127.58, 124.42, 123.39,
122.17, 120.31, 117.20, 109.76, 63.34, 52.79, 44.02, 40.81,
15.74. ESI–MS: (m/z) calculated for C22H21ClN4O3, calcu-
lated: 424.13, found: 425.21 (M+H)+. Anal. Calcd for
C22H21ClN4O3: (%) C 62.19, H 4.98, N 13.19. Found: C
62.26, H 5.05, N 13.24.
2.2.1.21. 5-(2-(4-(7-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-methylindolin-2-one (10u). Appearance: creamy
off white solid; mp = 203–204 C; FTIR: 3170, 3068, 1722,
1654, 1555, 1504, 1468, 902, 820. 1H NMR (400 MHz,
CDCl3) d 8.01 (d, J= 8.8 Hz, 1H), 7.83 (s, 1H), 7.69 (d,
J= 8.0 Hz, 1H), 7.54 (d, J= 8.0 Hz, 1H), 7.41 (m, 1H),
7.30 (d, J= 8.0 Hz, 1H), 3.89 (s, 2H), 3.72 (t, 4H), 3.60 (s,
2H), 3.36 (s, 3H), 2.57 (t, 4H). 13C NMR (100 MHz, CDCl3)
d 190.99, 178.24, 161.64, 159.22, 148.45, 131.75, 130.92,
129.36, 127.72, 124.81, 123.44, 122.66, 120.57, 116.96, 116.18,
63.14, 52.64, 43.80, 35.36, 34.78. ESI–MS: (m/z) calculated
for C22H21ClN4O3, calculated: 424.13, found: 425.24
(M+ H)+. Anal. Calcd for C22H21ClN4O3: (%) C 62.19, H
4.98, N 13.19. Found: C 62.27, H 5.02, N 13.22.2.2.1.22. 5-(2-(4-(7-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1,3-dimethylindolin-2-one (10v). Appearance: pale
yellow solid; mp = 208–209 C; FTIR: 3180, 3072, 1717,
1664, 1560, 1511, 1465, 900, 818. 1H NMR (400 MHz,
CDCl3) d 7.98 (d, J= 8.4 Hz, 1H), 7.90 (s, 1H), 7.66 (d,
J= 7.6 Hz, 1H), 7.57 (d, J= 8.0 Hz, 1H), 7.41 (m, 1H),
7.33 (s, 1H), 3.92 (s, 2H), 3.69 (t, 4H), 3.52 (q, 1H), 3.34 (s,
3H), 2.65 (t, 4H), 1.24 (d, J= 6.4 Hz, 3H). 13C NMR
(100 MHz, CDCl3) d 191.42, 179.08, 162.22, 159.35, 149.81,
132.22, 130.07, 129.71, 127.88, 124.65, 123.23, 122.31, 120.68,
116.98, 115.97, 63.63, 52.89, 43.87, 40.86, 34.25, 15.78. ESI–
MS: (m/z) calculated for C23H23ClN4O3, calculated: 438.14,
found: 439.25 (M+ H)+. Anal. Calcd for C23H23ClN4O3:
(%) C 62.94, H 5.28, N 12.77. Found: C 63.06, H 5.31, N
12.82.2.2.1.23. 5-(2-(4-(7-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-ethylindolin-2-one (10w). Appearance: yellow
solid; mp = 163–164 C; FTIR: 3181, 3070, 1718, 1662,
1567, 1512, 1468, 904, 819. 1H NMR (400 MHz, CDCl3) d
8.00 (d, J= 8.4 Hz, 1H), 7.85 (s, 1H), 7.769 (d, J= 8.0 Hz,
1H), 7.60 (d, J= 8.0 Hz, 1H), 7.40 (m, 1H), 7.33 (d,
J= 7.6 Hz, 1H), 3.88 (s, 2H), 3.80 (q, 2H), 3.64 (s, 2H), 3.63
(t, 4H), 2.52 (t, 4H), 1.22 (t, 3H). 13C NMR (100 MHz,
CDCl3) d 190.88, 179.73, 162.09, 159.21, 149.72, 132.31,
130.64, 129.45, 127.36, 124.38, 123.59, 122.44, 120.02, 116.77,
115.84, 63.48, 52.99, 43.82, 41.15, 36.13, 16.23. ESI–MS: (m/
z) calculated for C23H23ClN4O3, calculated: 438.14, found:
439.28 (M+ H)+. Anal. Calcd for C23H23ClN4O3: (%) C
62.94, H 5.28, N 12.77. Found: C 63.02, H 5.36, N 12.84.Please cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
dolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin -2-one analogues a
dx.doi.org/10.1016/j.arabjc.2015.02.0252.2.1.24. 5-(2-(4-(7-Chlorobenzo[d]isoxazol-3-yl)piperazin-1-
yl)acetyl)-1-ethyl-3-methylindolin-2-one (10x). Appearance:
pale yellow solid; mp = 149–151 C; FTIR: 3178, 3068,
1715, 1660, 1562, 1508, 1462, 908, 816. 1H NMR (400 MHz,
CDCl3) d 7.99 (d, J= 8.0 Hz, 1H), 7.92 (s, 1H), 7.74 (d,
J= 8.4 Hz, 1H), 7.63 (d, J= 8.0 Hz, 1H), 7.40 (m, 1H),
7.36 (s, 1H), 3.92 (s, 2H), 3.79 (q, 2H), 3.70 (t, 4H), 3.62 (q,
1H), 2.67 (t, 4H), 1.51 (d, J= 6.8 Hz, 3H), 1.32 (t, 3H). 13C
NMR (100 MHz, CDCl3) d 191.23, 179.68, 162.31, 159.45,
149.63, 132.84, 130.79, 129.23, 127.48, 124.21, 123.68, 122.24,
120.11, 116.89, 115.72, 63.79, 53.18, 43.78, 40.89, 39.88,
16.21, 15.45. ESI–MS: (m/z) calculated for C24H25ClN4O3, cal-
culated: 452.16, found: 453.28 (M+H)+. Anal. Calcd for
C24H25ClN4O3: (%) C 63.64, H 5.56, N 12.37. Found: C
63.72, H 5.62, N 12.44.
2.2.1.25. 5-(2-(4-(4-Nitrophenyl)piperazin-1-yl)acetyl)indolin-
2-one (12a). Appearance: yellow semi solid; mp = ND; FTIR:
3412, 3098, 3005, 1712, 1599, 1545, 1492, 1456, 1324, 995, 824.
1H NMR (400 MHz, CDCl3) d 8.93 (b, 1H), 8.59 (d,
J= 8.8 Hz, 2H), 7.95 (d, J= 8.4 Hz, 1H), 7.89 (d,
J= 8.0 Hz, 1H), 7.69 (s, 1H), 7.18 (d, J= 8.4 Hz, 2H), 3.80
(s, 2H), 3.72 (t, 4H), 3.51 (s, 2H), 2.65 (t, 4H). 13C NMR
(100 MHz, CDCl3) d 194.81, 174.78, 159.42, 148.22, 140.04,
137.54, 130.10, 129.64, 124.75, 124.53, 113.45, 108.08, 64.87,
53.45, 45.12, 34.08. ESI–MS: (m/z) calculated for
C20H20N4O4, calculated: 380.14, found: 381.22 (M+H)
+.
Anal. Calcd for C20H20N4O4: (%) C 63.15, H 5.30, N 14.73.
Found: C 63.23, H 5.39, N 14.82.
2.2.1.26. 3-Methyl-5-(2-(4-(4-nitrophenyl)piperazin-1-yl)acetyl)
indolin-2-one (12b). Appearance: yellow semi solid; mp=ND;
FTIR: 3418, 3128, 3015, 1714, 1610, 1548, 1498, 1454, 1322,
990, 821. 1H NMR (400 MHz, CDCl3) d 8.91 (b, 1H), 8.48 (d,
J= 9.2 Hz, 2H), 7.92 (d, J= 8.4 Hz, 1H), 7.86 (d, J= 8.0 Hz,
1H), 7.70 (s, 1H), 7.22 (d, J= 8.8 Hz, 2H), 3.80 (s, 2H), 3.72 (t,
4H), 3.64 (q, 1H), 2.62 (t, 4H), 1.30 (d, J= 6.4 Hz, 3H). 13C
NMR (100 MHz, CDCl3) d 194.02, 179.96, 158.03, 147.94,
139.67, 137.08, 130.34, 129.07, 125.12, 124.64, 114.45, 109.21,
65.01, 54.11, 46.07, 42.45, 18.19. ESI–MS: (m/z) calculated for
C21H22N4O4, calculated: 394.16, found: 395.24 (M+H)
+.
Anal. Calcd for C21H22N4O4: (%) C 63.95, H 5.62, N 14.20.
Found: C 63.86, H 5.68, N 14.26.
2.2.1.27. 1-methyl-5-(2-(4-(4-nitrophenyl)piperazin-1-yl)acetyl)
indolin-2-one (12c). Appearance: brown solid; mp = 209–
211 C; FTIR: 3124, 3018, 1718, 1613, 1557, 1499, 1450, 1328,
985, 820. 1H NMR (400 MHz, CDCl3) d 8.58 (d, J= 8.8 Hz,
2H), 8.01 (d, J= 8.4 Hz, 1H), 7.90 (s, 1H), 7.30 (d, J= 8.0 Hz,
1H), 7.18 (d, J= 8.4 Hz, 2H), 3.84 (s, 2H), 3.69 (t, 4H), 3.61 (s,
2H), 3.34 (s, 3H), 2.65 (t, 4H). 13C NMR (100 MHz, CDCl3) d
195.38, 176.01, 158.44, 148.17, 140.14, 137.58, 130.45, 129.88,
124.17, 123.58, 118.05, 114.38, 66.02, 55.15, 45.19, 36.05, 34.78.
ESI–MS: (m/z) calculated for C21H22N4O4, calculated: 394.16,
found: 395.28 (M+H)+. Anal. Calcd for C21H22N4O4: (%) C
63.95, H 5.62, N 14.20. Found: C 63.84, H 5.69, N 14.25.
2.2.1.28. 1,3-Dimethyl-5-(2-(4-(4-nitrophenyl)piperazin-1-yl)
acetyl)indolin-2-one (12d). Appearance: brown solid;
mp = 183–184 C; FTIR: 3140, 3012, 1721, 1610, 1555, 1500,
1452, 1329, 978, 822. 1H NMR (400 MHz, CDCl3) d 8.55 (d,
J= 9.2 Hz, 2H), 8.00 (d, J= 8.0 Hz, 1H), 7.99 (s, 1H), 7.42evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
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(t, 4H), 3.54 (q, 1H), 3.30 (s, 3H), 2.62 (t, 4H), 1.31 (d,
J= 6.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) d 194.14,
175.26, 157.80, 148.41, 140.68, 139.77, 131.48, 130.29, 124.44,
124.01, 121.00, 118.4, 65.58, 54.92, 44.88, 40.12, 34.55, 16.28.
ESI–MS: (m/z) calculated for C22H24N4O4, calculated: 408.17,
found: 409.24 (M+ H)+. Anal. Calcd for C22H24N4O4: (%)
C 64.69, H 5.92, N 13.72. Found: C 64.78, H 5.99, N 13.80.
2.2.1.29. 1-Ethyl-5-(2-(4-(4-nitrophenyl)piperazin-1-yl)acetyl)
indolin-2-one (12e). Appearance: brown solid; mp = 171–
173 C; FTIR: 3138, 3011, 1720, 1628, 1562, 1504, 1450,
1321, 982, 823. 1H NMR (400 MHz, CDCl3) d 8.56 (d,
J= 8.6 Hz, 2H), 8.05 (d, J= 8.4 Hz, 1H), 7.91 (s, 1H), 7.38
(d, J= 7.2 Hz, 1H), 7.22 (d, J= 8.0 Hz, 2H), 3.74 (s, 2H),
3.68 (q, 2H), 3.61 (t, 4H), 3.40 (s, 2H), 2.69 (t, 4H), 1.20 (t,
3H). 13C NMR (100 MHz, CDCl3) d 195.08, 174.84, 159.41,
148.00, 140.79, 137.54, 130.50, 129.63, 124.72, 124.49, 119.43,
115.88, 64.74, 53.87, 45.90, 36.08, 34.87, 13.79. ESI–MS: (m/
z) calculated for C22H24N4O4, calculated: 408.17, found:
409.28 (M+ H)+. Anal. Calcd for C22H24N4O4: (%) C
64.69, H 5.92, N 13.72. Found: C 64.79, H 5.97, N 13.82.
2.2.1.30. 1-Ethyl-3-methyl-5-(2-(4-(4-nitrophenyl)piperazin-1-
yl)acetyl)indolin-2-one (12f). Appearance: pale brown solid;
mp = 154–156 C; FTIR: 3145, 3009, 1724, 1625, 1560,
1509, 1452, 1324, 988, 826. 1H NMR (400 MHz, CDCl3) d
8.58 (d, J= 9.0 Hz, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.98 (s,
1H), 7.36 (d, J= 7.6 Hz, 1H), 7.18 (d, J= 8.0 Hz, 2H), 3.81
(s, 2H), 3.74 (q, 2H), 3.65 (t, 4H), 3.51 (q, 1H), 2.72 (t, 4H),
1.29 (t, 3H), 1.21 (d, J= 6.4 Hz, 3H),. 13C NMR (100 MHz,
CDCl3) d 195.12, 178.01, 158.56, 148.24, 141.03, 138.22,
130.78, 129.95, 125.83, 124.72, 121.08, 116.64, 65.02, 53.45,
45.18, 39.87, 38.04, 16.85, 14.82. ESI–MS: (m/z) calculated
for C23H26N4O4, calculated: 422.19, found: 423.26
(M+H)+. Anal. Calcd for C23H26N4O4: (%) C 65.39, H
6.20, N 13.26. Found: C 65.51, H 6.27, N 13.34.
2.2.1.31. 5-(2-(4-(Pyridin-2-yl)piperazin-1-yl)acetyl)indolin-2-
one (12g). Appearance: dark brown semi solid; mp = ND;
FTIR: 3421, 3099, 3012, 1720, 1622, 1508, 1450, 1314, 990,
822. 1H NMR (400 MHz, CDCl3) d 8.82 (b, 1H), 8.15 (d,
J= 3.6 Hz, 1H), 8.08 (d, J= 7.6 Hz, 1H), 7.88 (d,
J= 8.0 Hz, 1H), 7.68 (s, 1H), 7.63 (m, 1H), 7.14 (d,
J= 8.0 Hz, 1H), 6.96 (m, 1H), 3.81 (s, 2H), 3.73 (t, 4H),
3.49 (s, 2H), 2.64 (t, 4H). 13C NMR (100 MHz, CDCl3) d
193.88, 173.78, 159.02, 148.84, 147.90, 138.06, 130.28, 129.84,
125.11, 124.52, 120.00, 110.74, 108.14, 64.84, 54.09, 45.27,
35.12. ESI–MS: (m/z) calculated for C19H20N4O2, calculated:
336.15, found: 337.08 (M+ H)+. Anal. Calcd for
C19H20N4O2: (%) C 67.84, H 5.99, N 16.66. Found: C 67.91,
H 6.07, N 16.74.
2.2.1.32. 3-Methyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)acetyl)
indolin-2-one (12h). Appearance: brown solid; mp = 173–
174 C; FTIR: 3424, 3095, 3011, 1722, 1630, 1515, 1454,
1318, 991, 824. 1H NMR (400 MHz, CDCl3) d 8.90 (b, 1H),
8.18 (d, J= 4.0 Hz, 1H), 8.10 (d, J= 7.6 Hz, 1H), 7.90 (d,
J= 8.0 Hz, 1H), 7.72 (s, 1H), 7.61 (m, 1H), 7.18 (d,
J= 8.0 Hz, 1H), 6.98 (m, 1H), 3.83 (s, 2H), 3.72 (t, 4H),
3.69 (q, 1H), 2.60 (t, 4H), 1.31 (d, J= 6.4 Hz, 3H). 13C
NMR (100 MHz, CDCl3) d 194.75, 173.99, 159.38, 148.91,Please cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
dolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin -2-one analogues a
dx.doi.org/10.1016/j.arabjc.2015.02.025147.92, 137.62, 130.41, 129.60, 124.71, 124.50, 119.22, 111.54,
107.89, 64.09, 53.44, 45.06, 41.08, 14.67. ESI–MS: (m/z) calcu-
lated for C20H22N4O2, calculated: 350.17, found: 351.24
(M+H)+. Anal. Calcd for C20H22N4O2: (%) C 68.55, H
6.33, N 15.99. Found: C 68.61, H 6.39, N 16.08.
2.2.1.33. 1-Methyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)acetyl)
indolin-2-one (12i). Appearance: dark brown solid;
mp = 188–189 C; FTIR: 3099, 3002, 1719, 1638, 1518,
1451, 1315, 985, 821. 1H NMR (400 MHz, CDCl3) d 8.17 (d,
J= 4.0 Hz, 1H), 8.05 (d, J= 7.6 Hz, 1H), 7.92 (s, 1H), 7.51
(m, 1H), 6.92 (d, J= 8.0 Hz, 1H), 6.89 (d, J= 8.0 Hz, 1H),
6.81 (m, 1H), 3.82 (s, 2H), 3.70 (t, 4H), 3.59 (s, 2H), 3.32 (s,
3H), 2.56 (t, 4H). 13C NMR (100 MHz, CDCl3) d 194.24,
174.67, 159.44, 148.80, 147.87, 137.59, 130.73, 129.22, 125.42,
124.09, 118.15, 110.87, 108.14, 64.53, 53.35, 44.88, 37.22,
33.14. ESI–MS: (m/z) calculated for C20H22N4O2, calculated:
350.17, found: 351.25 (M+ H)+. Anal. Calcd for
C20H22N4O2: (%) C 68.55, H 6.33, N 15.99. Found: C 68.63,
H 6.37, N 16.06.
2.2.1.34. 1,3-Dimethyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)ace-
tyl)indolin-2-one (12j). Appearance: dark brown solid;
mp = 154–155 C; FTIR: 3105, 3010, 1721, 1642, 1524, 1450,
1314, 988, 820. 1H NMR (400 MHz, CDCl3) d 8.14 (d,
J= 4.4 Hz, 1H), 8.02 (d, J= 7.2 Hz, 1H), 7.94 (s, 1H), 7.63
(m, 1H), 7.18 (d, J= 8.0 Hz, 1H), 6.94 (d, J= 8.0 Hz, 1H),
6.88 (m, 1H), 3.86 (s, 2H), 3.68 (t, 4H), 3.59 (q, 1H), 3.31 (s,
3H), 2.63 (t, 4H), 1.34 (d, J= 6.0 Hz, 3H). 13C NMR
(100 MHz, CDCl3) d 194.69, 174.11, 159.35, 148.90, 147.94,
138.01, 130.38, 129.72, 124.58, 124.44, 115.82, 108.12, 107.91,
64.50, 53.40, 45.95, 36.04, 35.76, 17.08. ESI–MS: (m/z) calculated
for C21H24N4O2, calculated: 364.18, found: 365.26 (M+H)
+.
Anal. Calcd for C21H24N4O2: (%) C 69.21, H 6.64, N 15.37.
Found: C 69.32, H 6.69, N 15.44.
2.2.1.35. 1-Ethyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)acetyl)
indolin-2-one (12k). Appearance: dark brown solid;
mp = 133–134 C; FTIR: 3112, 3011, 1720, 1640, 1528,
1452, 1318, 992, 824. 1H NMR (400 MHz, CDCl3) d 8.19 (d,
J= 3.2 Hz, 1H), 8.07 (d, J= 7.2 Hz, 1H), 7.95 (s, 1H), 7.50
(m, 1H), 6.89 (d, J= 8.0 Hz, 1H), 6.66 (d, J= 8.0 Hz, 1H),
6.63 (m, 1H), 3.82 (s, 2H), 3.79 (q, 2H), 3.63 (t, 4H), 3.49 (s,
2H), 2.72 (t, 4H), 1.30 (t, 3H). 13C NMR (100 MHz, CDCl3)
d 194.81, 174.84, 159.43, 148.83, 147.90, 137.50, 130.41,
129.60, 124.71, 124.52, 113.43, 107.66, 107.11, 64.44, 53.34,
45.07, 35.48, 34.87, 12.72. ESI–MS: (m/z) calculated for
C21H24N4O2, calculated: 364.18, found: 365.22 (M+ H)
+.
Anal. Calcd for C21H24N4O2: (%) C 69.21, H 6.64, N 15.37.
Found: C 69.34, H 6.68, N 15.46.
2.2.1.36. 1-Ethyl-3-methyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)
acetyl)indolin-2-one (12l). Appearance: brown solid;
mp = 128–130 C; FTIR: 3114, 3008, 1718, 1644, 1527, 1455,
1322, 990, 823. 1H NMR (400 MHz, CDCl3) d 8.16 (d,
J= 3.6 Hz, 1H), 8.08 (d, J= 7.6 Hz, 1H), 7.97 (s, 1H), 7.52
(m, 1H), 6.94 (d, J= 8.0 Hz, 1H), 6.73 (d, J= 8.0 Hz, 1H),
6.68 (m, 1H), 3.87 (s, 2H), 3.78 (q, 2H), 3.66 (t, 4H), 3.54 (q,
1H), 2.76 (t, 4H), 1.51 (t, 3H), 1.33 (d, J= 6.8 Hz, 3H). 13C
NMR (100 MHz, CDCl3) d 194.84, 175.02, 159.22 149.23,
147.94, 137.72, 131.22, 129.82, 124.74, 124.66, 114.48, 108.89,
107.76, 65.12, 53.88, 45.21, 39.84, 35.90, 13.34, 13.08. ESI–MS:evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
Scheme 1 General synthetic route to achieve the title compounds. Reagents and conditions: (i) Chloroacetyl chloride/2-chloropropanoyl
chloride (1.1 equiv.), N(C2H5)3 (2.0 equiv.), DCM, 0 C – rt, 1 h; (ii) AlCl3 (3.0 equiv.), 130 C, 4 h; (iii) Chloroacetyl chloride (1.5 equiv.),
AlCl3 (3.0 equiv.), DCM, rt, 4 h; (iv) NH2OHHCl (1.2 equiv.), CH3COONa (2.0 equiv.), EtOH, H2O, C-rt, 1 h; (v)
N-Chlorosuccinimide (1.2 equiv.), CCl4, 0 C – rt, 45 min; (vi) Piperazine (8.0 equiv.), N(C2H5)3 (2.0 equiv.), CH2Cl2, rt, 2 h; (vii) 30%
KOH (3.0 equiv.), Dioxane, 120 C, 4 h, (65–90%); (viii and ix) K2CO3 (1.2 equiv.), acetonitrile, lW, 80 C, 8 min.
8 K.M. Naidu et al.(m/z) calculated for C22H26N4O2, calculated: 378.20, found:
379.32 (M+H)+. Anal. Calcd for C22H26N4O2: (%) C 69.82,
H 6.92, N 14.80. Found: C 69.91, H 6.99, N 14.93.2.3. Microplate Alamar Blue Assay (MABA)
The anti-TB activities of title analogues 10a–x and 12a–l were
evaluated against MTB H37Rv (ATCC 27294) strain using
MABA (Franzblau et al., 1998; Collins et al., 1997).
Isoniazid, rifampin and pyrazinamide are used as positive con-
trols. Compound stock solutions were prepared in DMSO at a
concentration 100 mg/mL, and the ﬁnal test concentrations
ranged from 50 to 0.78 lg/mL. Twofold serial dilutions of
compounds were prepared in Middlebrook 7H9GC medium
in a volume of 100 mL in 96-well microplates. TB culture
(100 mL inoculum of 2 · 105 CFU/mL) was added, yielding
a ﬁnal testing volume of 200 mL. The plates were incubated
at 37 C. On the seventh day of incubation 25 lL of 10%
Tween 80 and 25 mL of Alamar Blue (Accumed
International, Westlake, Ohio) were added to the wells of test
plate. After incubation at 37 C for 24 h, colours of all wells
were recorded. A blue colour in the well was interpreted as
no growth, and a pink colour was scored as growth. ThePlease cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
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vented a colour change from blue to pink.
2.4. Cytotoxicity assay
Furthermore, most active anti-TB compounds (66.25 lg/mL)
were analysed for Cytotoxicity in RAW 264.7 cell line at con-
centration of 50 lg/mL. Selectivity index of the compounds
was also determined. After 72 h of exposure, viability was
evaluated on the basis of cellular conversion of 3-(4, 5-dimethy-
lthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) into a
formazan product using the Promega Cell Titer 96 non-radioac-
tive cell proliferation assay. MTT, a yellow tetrazole, is reduced
to purple formazan in living cells which is further quantiﬁed
spectrophotometrically (Gerlier et al., 1986).
3. Results and discussion
3.1. Chemistry
In the present report, we synthesized 5-(2-(4-(benzo[d]isoxazol-
3-yl)piperazin-1-yl)acetyl)indolin-2-one and 5-(2-(4-(pyridin-2-
yl)piperazin-1-yl)acetyl)indolin-2-one derivatives as depictedevaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
Table 1 Anti-tubercular activities of compounds 10a–x and 12a–l against MTB H37Rv.
Entry R1 R2 R3 X % Yield MIC (lg/mL) against MTB H37Rv
10a H H – H 63 50
10b H CH3 – H 60 25
10c CH3 H – H 84 6.25
10d CH3 CH3 – H 79 6.25
10e C2H5 H – H 91 3.12
10f C2H5 CH3 – H 83 1.56
10g H H – 4-Cl 60 25
10h H CH3 – 4-Cl 62 25
10i CH3 H – 4-Cl 81 12.5
10j CH3 CH3 – 4-Cl 90 6.25
10k C2H5 H – 4-Cl 88 1.56
10l C2H5 CH3 – 4-Cl 82 3.12
10m H H – 6-Cl 65 >50
10n H CH3 – 6-Cl 60 12.5
10o CH3 H – 6-Cl 94 6.25
10p CH3 CH3 – 6-Cl 89 1.56
10q C2H5 H – 6-Cl 81 3.12
10r C2H5 CH3 – 6-Cl 80 1.56
10s H H – 7-Cl 67 >50
10t H CH3 – 7-Cl 63 50
10u CH3 H – 7-Cl 92 12.5
10v CH3 CH3 – 7-Cl 86 6.25
10w C2H5 H 7-Cl 84 3.12
10x C2H5 CH3 – 7-Cl 90 3.12
12a H H 4-NO2Ph – 61 25
12b H CH3 4-NO2Ph – 65 50
12c CH3 H 4-NO2Ph – 78 12.5
12d CH3 CH3 4-NO2Ph – 85 3.12
12e C2H5 H 4-NO2Ph – 88 3.12
12f C2H5 CH3 4-NO2Ph – 81 1.56
12g H H 2-Pyridyl – 60 25
12h H CH3 2-Pyridyl – 62 25
12i CH3 H 2-Pyridyl – 78 3.12
12j CH3 CH3 2-Pyridyl – 84 1.56
12k C2H5 H 2-Pyridyl – 80 1.56
12l C2H5 CH3 2-Pyridyl – 91 3.12
INH – – – – – 0.1
RFA – – – – – 0.2
PZA – – – – – 6.25
Design, synthesis and biological evaluation 9in Scheme 1. TheN-substituted aniline (1a–c) on treatment with
2-chloroacetyl chloride/2-chloropropanoyl chloride and
N(C2H5)3 in Dichloro methane (DCM) at 0 C – rt for 1 h
yielded 2-chloro-N-substituted-N-phenyl amide derivatives
(2a–f). Further cyclization with AlCl3 under solvent free condi-
tions at 130 C for 4 h afforded substituted indolin-2-one
derivatives (3a–f). Substituted 5-(2-chloroacetyl)indolin-2-ones
(4a–f) were synthesized by reacting 2-chloroacetyl chloride with
anhydrous AlCl3 in CH2Cl2 at rt for 4 h. Substituted 2-
chlorobenzaldehyde (5a–d) on treatment with NH2OHÆHCl
and CH3COONa in EtOH and H2O at 0 C – rt for 1 h yielded
oxime derivatives (6a–d). Further chlorination with N-chloro-
succinimide in CCl4 at 0 C – rt for 45 min afforded substituted
2-chloro-N-hydroxybenzimidoyl chloride derivatives (7a–d).
Substituted (2-chlorophenyl) (piperazin-1-yl)methanone oxi-
mes (8a–d) were synthesized by reacting 7a–d with anhydrous
piperazine and N(C2H5)3 in CH2Cl2 at rt. 9a–d was synthesized
from 8a–d by reacting with 30% KOH in aqueous dioxane at
120 C.
Final compounds, 10a–x and 12a–l were synthesized by
reﬂuxing a mixture of 3-(piperazin-1-yl)benzo[d]isoxazolePlease cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
dolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin -2-one analogues a
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oxindole derivatives (4a–f) and anhydrous potassium carbon-
ate using acetonitrile in microwave oven for 8 min. All the syn-
thesized compounds were conﬁrmed by 1H NMR, 13C NMR,
IR, LCMS and Elemental analyses. In general, the 1H NMR
showed singlets and multiplets in aliphatic region 1.12–4.45,
multiplets in the range 3.22–3.68 ppm due to piperazine
(-CH2-) protons, aromatic protons of substituted oxindole
group and benzisoxazole appeared at 6.48–9.42 ppm and
amine group at 9.10–10.45. 13C NMR showed carbonyl group
at 172–196, aromatic carbons in the range of 107–168 ppm and
piperazine carbons in the range of 42–68 ppm. Absence of NH
stretching peak at 3228 cm1 in the title compounds, 10a–x
and 12a–l, conﬁrms the formation of products.
3.2. Antimycobacterial activity
All the synthesized analogues are tested for anti-TB activity
against MTB H37Rv (ATCC 27294) strain by MABA with
compound concentration ranging from 50 to 0.78 lg/mL.
Isoniazid, Rifampin and Pyrazinamide were used as theevaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
Table 2 IC50 (lg/mL) and SI values of active compounds.
S. no. Compound MIC (lg/mL)
in MTB H37Rv
% Cell inhibition
at 50 lg/mL
IC50 approximation
aSI value
1 10c 6.25 35.62 70.18 11.22
2 10d 6.25 22.80 109.64 17.54
3 10e 3.12 38.42 65.07 20.85
4 10f 1.56 36.46 68.56 43.95
5 10j 6.25 38.10 65.61 10.49
6 10k 1.56 35.62 70.18 44.99
7 10l 3.12 40.40 61.88 19.83
8 10o 6.25 42.80 58.41 9.34
9 10p 1.56 46.43 53.84 34.51
10 10q 3.12 31.76 78.71 25.22
11 10r 1.56 44.60 56.05 35.93
12 10v 6.25 28.92 86.44 13.83
13 10w 3.12 30.16 82.89 26.56
14 10x 3.12 22.16 112.81 36.15
15 12d 3.12 35.62 70.18 22.49
16 12e 3.12 40.40 61.88 19.83
17 12f 1.56 30.72 81.38 52.16
18 12i 3.12 19.16 130.48 41.82
19 12j 1.56 22.12 113.01 72.44
20 12k 1.56 26.52 94.26 60.42
a Selectivity index.
10 K.M. Naidu et al.positive drug standards. The in vitro antimycobacterial results
of title compounds are tabulated in Table 1 as MIC and the
activity ranged between 1.56 and 50 lg/mL. The compounds
10c, 10d, 10j, 10o and 10v displayed moderate activity (MIC
6.25 lg/mL), whereas chemo synthetics 10e, 10l, 10q,
10w,10x, 12d, 12e and 12i showed good anti-TB activity
(MIC 3.12 lg/mL) and few analogues 10f, 10k, 10p, 10r, 12f,
12j and 12k exhibited excellent anti-TB activity (MIC
1.56 lg/mL). Compounds with MIC 6 6.25 lg/mL were sub-
jected to cytotoxicity studies.
Among the analogues, compounds 10f, 10k, 10p, 10r, 12f,
12j and 12k emerged as the most auspicious entrants by
inhibiting 99% growth of MTB H37Rv strain at concentration
of 1.56 lg/mL. Electronic effects of substituent play a vital role
in exhibiting anti-TB activity. SAR studies for Oxindole ben-
zisoxazole derivatives (10a–x) and Oxindole piperazine ana-
logues (12a–l) are described based on activity of compound
10a. Presence of electron donating methyl or ethyl groups at
1st position on oxindole, greatly enhanced the anti-TB activity
by 4–32 fold with MIC 12.5–1.56 lg/mL. However, unsub-
stitution at 1st position of oxindole resulted in one fold
increase in activity (10b, 10g, 10h, 10n, 12a, 12g and 12h) or
retention of anti-TB activity (10t and 12b) or decrease in
anti-TB activity (10m and 10s). Presence of chlorine at 4th,
6th and 7th position of benzisoxazole moiety or its absence,
did not impact the activity. In totality, we observe that piper-
azine analogues (12a–l) were more active than the benzisoxa-
zole analogues (10a–x).
3.3. Cytotoxicity
The compounds with MIC 6 6.25 lg/mL were subjected to
Promega Cell Titer 96 non-radioactive cell proliferation assay
to analyse the selectivity proﬁle against mouse macrophagePlease cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
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(SI) values (Kamal et al., 2013) are tabulated in Table 2. We
notice that most active compounds 10f, 10k, 10p, 10r, 12f,
12j and 12k with MIC 1.56 lg/mL, have SIP 34 indicating
the appropriation of the chemophores in further drug
development.
4. Conclusion
In conclusion, a series of 5-(2-(4-(benzo[d]isoxazol-3-yl)pipera-
zin-1-yl)acetyl)indolin-2-one and 5-(2-(4-(pyridin-2-yl)pipera-
zin-1-yl)acetyl)indolin-2-one analogues were synthesized in
moderate to excellent yields. Out of 36 derivatives synthesized
7 analogues (10f, 10k, 10p, 10r, 12f, 12j and 12k) unveiled
excellent anti-TB activity with MIC 1.56 lg/mL. The most
active compounds exhibited good selectivity proﬁle. This out-
come indicates that novel chemophores are not toxic and
might be considered for further structural modiﬁcation. The
observed potency of these compounds against MTB encour-
ages further optimization of the hybrid of oxindole, piperazine
and benzo[d]isoxazoles to produce essential pharmacophoric
features that might lead to the promising candidate in develop-
ing anti-tubercular agents.
Acknowledgements
We acknowledge the ﬁnancial assistance provided by
Department of Science & Technology (No. SB/S1/OC-60/
2013), New Delhi, India. We also gratefully acknowledge the
assistance provided by Antimycobacterial Research
Laboratory, Department of Pharmacy, BITS Pilani
Hyderabad Campus in carrying out the anti-TB screening.
KMN is thankful to BITS Pilani, Hyderabad Campus, for
award of institute fellowship.evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
Design, synthesis and biological evaluation 11References
Ashish, K.K., Dahiya, N., 2014. Bedaquiline for the treatment of
resistant tuberculosis: promises and pitfalls. Tuberculosis 94, 357–
362.
Bramson, H.N., Corona, J., Davis, S.T., Dickerson, S.H., Edelstein,
M., Frye, S.V., Gampe, R.T., Harris Jr., P.A., Hassell, A., Holmes,
W.D., Hunter, R.N., Lackey, K.E., Lovejoy, K.E., Luzzio, M.J.,
Montana, V., Rocque, W.J., Rusnak, D., Shewchuk, L., Veal,
J.M., Walker, D.H., Kuyper, L.F., 2001. Oxindole-based inhibitors
of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic
activities, and X-ray crystallographic analysis. J. Med. Chem. 44,
4339–4358.
Chande, M.S., Verma, R.S., Barve, P.A., Khanwelkar, R.R., Vaidya,
R.B., Ajaikumar, K.B., 2005. Facile synthesis of active antituber-
cular, cytotoxic and antibacterial agents: a Michael addition
approach. Eur. J. Med. Chem. 40, 1143–1148.
Chen, Y., Wang, S., Xu, X., Liu, X., Yu, M., Zhao, S., Liu, S., Qiu, Y.,
Zhang, T., Liu, B.-F., Zhang, G., 2013. Synthesis and biological
investigation of coumarin piperazine (piperidine) derivatives as
potential multireceptor atypical antipsychotics. J. Med. Chem. 56,
4671–4690.
Collins, L.A., Franzblau, S.G., 1997. Microplate Alamar blue assay
versus BACTEC 460 system for high- throughput screening of
compounds againstMycobacterium tuberculosis andMycobacterium
avium. Antimicrob. Agents Chemother. 41, 1004–1009.
Deng, B.-L., Cullen, M.D., Zhou, Z., Hartman, T.L., Buckheit Jr.,
R.W., Pannecouque, C., Clercq, E.D., Fanwick, P.E., Cushman,
M., 2006. Synthesis and anti-HIV activity of new alkenyldiaryl-
methane (ADAM) non-nucleoside reverse transcriptase inhibitors
(NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
Bioorg. Med. Chem. 14, 2366–2374.
Deng, B.-L., Zhao, Y., Hartman, Y.L., Watson, K., Buckheit Jr.,
R.W., Pannecouque, C., Clercq, E.D., Cushman, M., 2009.
Synthesis of alkenyldiarylmethanes (ADAMs) containing
benzo[d]isoxazole and oxazolidin-2-one rings, a new series of
potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur.
J. Med. Chem. 44, 1210–1214.
Eissenstat, M., Guerassina, T., Gulnik, S., Afonina, E., Silva, A.M.,
Ludtke, D., Yokoe, H., Yu, B., Erickson, J., 2012. Enamino-
oxindole HIV protease inhibitors. Bioorg. Med. Chem. Lett. 22,
5078–5083.
Fensome, A., Bender, R., Cohen, J., Collins, M.A., Mackner, V.A.,
Miller, L.L., Ullrich, J.W., Winneker, R., Wrobel, J., Zhang, P.,
Zhang, Z., Zhu, Y., 2002. Bioorg. Med. Chem. Lett. 12, 3487–3490.
Franzblau, S.G., Witzig, R.S., McLaughlin, J.C., Torres, P., Madico,
G., Hernandez, A., Degnan, M.T., Cook, M.B., Quenzer, V.K.,
Ferguson, R.M., Gilman, R.H., 1998. Rapid, low-technology MIC
determination with clinical Mycobacterium tuberculosis isolates by
using the microplate Alamar Blue assay. J. Clin. Microb. 36, 362–
366.
Gerlier, D., Thomasset, N., 1986. Use of MTT colorimetric assay to
measure cell activation. Immunol. Methods 94, 57–63.
Guzel, O., Karalı, N., Salman, A., 2008. Synthesis and antituberculosis
activity of 5-methyl/triﬂuoromethoxy-1H-indole-2,3-dione 3-
thiosemicarbazone derivatives. Bioorg. Med. Chem. 16, 8976–8987.
Hanada, K., 2004. ‘‘Serine palmitoyltransferase, a key enzyme of
sphingolipid metabolism’’ Biochim. Biophys. Acta 1682, 128.
Howard, H.R., Lowe, J.A., Seeger, T.F., Seymour, P.A., Zorn, S.H.,
Maloney, P.R., Ewing, F.E., Newman, M.E., Schmidt, A.W.,
Furman, J.S., Robinson, G.L., Jackson, S., Johnson, C., Morrone,
J., 1996. 3-Benzisothiazolylpiperazine derivatives as potential
atypical antipsychotic agents. J. Med. Chem. 39, 143–148.
Kakwani, M.D., Suryavanshi, P., Ray, M., Rajan, M.G.R., Majee, S.,
Samad, A., Devarajan, P., Degani, M.S., 2011. Design, synthesis
and antimycobacterial activity of cinnamide derivatives: a molecu-
lar hybridization approach. Bioorg. Med. Chem. Lett. 21, 1997–
1999.Please cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
dolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin -2-one analogues a
dx.doi.org/10.1016/j.arabjc.2015.02.025Kamal, A., Swapna, P., Shetti, R.V.C.R.N.C., Shaik, A.B., Narasimha
Rao, M.P., Sultana, F., Khan, I.A., Sharma, S., Kalia, N.P.,
Kumar, S., Chandrakant, B., 2013. Anti-tubercular agents. Part 7:
A new class of diarylpyrrole–oxazolidinone conjugates as antimy-
cobacterial agents. Eur. J. Med. Chem. 64, 239–251.
Karali, N., Gursoy, A., Kandemirli, F., Shvets, N., Kaynak, F.B.,
Ozbey, S., Kovalishyn, V., Dimoglo, A., 2007. Synthesis and
structure-antituberculosis activity relationship of 1H-indole-2,3-
dione derivatives. Bioorg. Med. Chem. 15, 5888–5904.
Kiser, E.J., Magano, J., Shine, R.J., Chen, M.H., 2012. Kilogram-lab-
scale oxindole synthesis via palladium-catalyzed C–H func-
tionalization. Org. Process Res. Dev. 16, 255–259.
Malik, S., Ahuja, P., Sahu, K., Khan, S.A., 2014. Design and synthesis
of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2,5-
dione derivatives as anticonvulsants. Eur. J. Med. Chem. 84, 42–50.
Mannaioni, G., Carpenedo, R., Pugliese, A.M., Corradetti, R.,
Moroni, F., 1998. Electrophysiological studies on oxindole, a
neurodepressant tryptophan metabolite. Br. J. Pharmacol. 125,
1751–1760.
Monish, J., Chul-Hoon, K., 2003. 1,2-Benzisoxazole phosphorodiami-
dates as novel anticancer prodrugs requiring bioreductive activa-
tion. J. Med. Chem. 46, 5428–5436.
Mortenson, P.N., Murray, C.W., 2011. Assessing the lipophilicity of
fragments and early hits. J. Comput. Aided Mol. Des. 25, 663–667.
Nagesh, H.N., Suresh, N., Naidu, K.M., Arun, B., Sridevi, J.P.,
Sriram, D., Yogeeswari, P., Chandra Sekhar, K.V.G., 2014.
Synthesis and evaluation of anti-tubercular activity of 6-(4-substi-
tutedpiperazin-1-yl) phenanthridine analogues. Eur. J. Med. Chem.
74, 333–339.
Naidu, K.M., Suresh, A., Subbalakshmi, J., Sriram, D., Yogeeswari,
P., Raghavaiah, P., Chandra Sekhar, K.V.G., 2014. Design,
synthesis and antimycobacterial activity of various 3-(4-(substi-
tutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives. Eur. J.
Med. Chem. 87, 71–78.
Natarajan, A., Guo, Y., Harbinski, F., Fan, Y.-H., Chen, H., Luus, L.,
Diercks, J., Aktas, H., Chorev, M., Halperin, J.A., 2004. Novel
arylsulfoanilide–oxindole hybrid as an anticancer agent that
inhibits translation initiation. J. Med. Chem. 47, 4979–4982.
Patel, K.N., Telvekar, V.N., 2014. Design, synthesis and antituber-
cular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cin-
namamide derivatives. Eur. J. Med. Chem. 75, 43–56.
Prathima, P.S., Rajesh, Rao, J.V., Kailash, U.S., Sridhar, B., Rao,
M.M., 2014. ‘‘On water’’ expedient synthesis of 3-indolyl-3-
hydroxy Oxindole derivatives and their anticancer activity
in vitro. Eur. J. Med. Chem. 84, 155–159.
Priya, B.S., Basappa, Swamy, S.N., Rangappa, K.S., 2005. Synthesis
and characterization of novel 6-ﬂuoro-4-piperidinyl-1,2-benzisoxa-
zole amides and 6-ﬂuoro-chroman-2-carboxamides: antimicrobial
studies. Bioorg. Med. Chem. 13, 2623–2628.
Punkvang, A., Saparpakorn, P., Hannongbua, S., Wolschann, P.,
Beyer, A., Pungpo, P., 2010. Investigating the structural basis of
arylamides to improve potency against M. tuberculosis strain
through molecular dynamics simulations. Eur. J. Med. Chem. 45,
5585–5593.
Ranjith Kumar, R., Subbu, P., Senthilkumar, P., Yogeeswari, P.,
Sriram, D., 2009. A facile synthesis and antimycobacterial evalua-
tion of novel spiro-pyrido-pyrrolizines and pyrrolidines. Eur. J.
Med. Chem. 44, 3821–3829.
Shantharam, C.S., Vardhan, D.M.S., Suhas, R., Sridhara, M.B.,
Gowda, D.C., 2013. Inhibition of protein glycation by urea and
thiourea derivatives of glycine/proline conjugated benzisoxazole
analogue – synthesis and structure–activity studies. Eur. J. Med.
Chem. 60, 325–332.
Singh, H., Sindhu, J., Khurana, J.M., Sharma, C., Aneja, K.R., 2014.
Ultrasound promoted one pot synthesis of novel ﬂuorescent
triazolyl spirocyclic oxindoles using DBU based task speciﬁc ionic
liquids and their antimicrobial activity. Eur. J. Med. Chem. 77,
145–154.evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
12 K.M. Naidu et al.Sriram, D., Aubry, A., Yogeeswari, P., Fisher, L.M., 2006.
Gatiﬂoxacin derivatives: synthesis, antimycobacterial activities,
and inhibition of Mycobacterium tuberculosis DNA gyrase.
Bioorg. Med. Chem. Lett. 16, 2982–2985.
Strupczewski, J.T., Bordeau, K.J., Chiang, Y., Glamkowski, E.J.,
Conway, P.G., Corbett, R., Hartman, H.B., Szewczak, M.R.,
Wilmot, C.A., Helsley, G.C., 1995. 3-[(Aryloxy)alkyllpiperidinyl]-
l,2-Benzisoxazoleass D2/5-HT2 antagonists with potential atypical
antipsychotic activity: antipsychotic proﬁle of Iloperidone (HP
873). J. Med. Chem. 38, 1119–1131.
Subash, V., Michael, B., Reaz, U., Baojie, W., Scott, G.F., Pavel, A.P.,
2008. 5-tert-Butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxa-
zole-3-carboxamide derivatives as novel potent inhibitors of
mycobacterium tuberculosis pantothenate synthetase: initiating a
quest for new antitubercular drugs. J. Med. Chem. 51, 1999–2002.
Suhas, R., Chandrashekar, S., Gowda, D.C., 2009. Synthesis of elastin
based peptides conjugated to benzisoxazole as a new class of potent
antimicrobials – a novel approach to enhance biocompatibility.
Eur. J. Med. Chem. 46, 704–711.
Sumpter, W.C., 1945. The chemistry of oxindole. Chem. Rev. 37, 443–
479.
Tangallapally, R.P., Yendapally, R., Lee, R.E., Lenaerts, A.J.M., Lee,
R.E., 2005. Synthesis and evaluation of cyclic secondary amine
substituted phenyl and benzyl Nitrofuranyl amides as novel
Antituberculosis Agents. J. Med. Chem. 48, 8261–8269.
Thomas, K.D., Adhikari, A.V., Chowdhury, I.H., Sumesh, E., Pal,
N.K., 2011. New quinolin-4-yl-1,2,3-triazoles carrying amides,
sulphonamides and amidopiperazines as potential antitubercular
agents. Eur. J. Med. Chem. 46, 2503–2512.
Tokunaga, T., Hume, W.E., Nagamine, J., Kawamura, T., Taiji, M.,
Nagata, R., 2005. Structure–activity relationships of the oxindolePlease cite this article in press as: Naidu, K.M. et al., Design, synthesis and biological
dolin-2-one and 5-(2-(4-substitutedpiperazin-1-yl)acetyl)indolin -2-one analogues a
dx.doi.org/10.1016/j.arabjc.2015.02.025growth hormone secretagogues. Bioorg. Med. Chem. Lett. 15,
1789–1792.
Tourneau, C.L., Raymond, E., Faivre, S., 2007. Sunitinib: a novel
tyrosine kinase inhibitor. A brief review of its therapeutic potential
in the treatment of renal carcinoma and gastrointestinal stromal
tumors (GIST). Ther. Clin. Risk Manag. 3, 341–348.
Uno, H., Kurokawa, M., Masuda, Y., Nishimura, H., 1979. Studies on
3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-
(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their
Anticonvulsant activities. J. Med. Chem. 22, 180–183.
Villalobos, A., Blake, J.F., Biggers, C.K., Butler, T.W., Chapin, D.C.,
Chen, Y.L., Ives, J.L., Jones, S.B., Liston, D.R., Nagel, A.A.,
Nason, D.M., Nielsen, J.A., Shalaby, I.A., White, W.F., 1994.
Novel Benzisoxazole derivatives as potent and selective inhibitors
of Acetylcholinesterase. J. Med. Chem. 37, 2721–2734.
World Health Organization (WHO) – Global Tuberculosis Control
report. Geneva, Switzerland, 2014a. <http://www.who.int/tb/pub-
lications/global_report/en/>.
World Health Organization (WHO) – Global Tuberculosis factsheet.
Geneva, Switzerland, 2014b. <http://www.who.int/tb/pub-
lications/factsheet_global.pdf>.
Woodard, C.L., Li, Z., Kathcart, A.K., Terrell, J., Gerena, L., Lopez-
Sanchez, M., Kyle, D.E., Bhattacharjee, A.K., Nichols, D.A., Ellis,
W., Prigge, S.T., GeyerJ, A., Waters, N.C., 2003. Oxindole-based
compounds are selective inhibitors of Plasmodium falciparum cyclin
dependent protein kinases. J. Med. Chem. 46, 3877–3882.
Yasuda, D., Takahashi, K., Ohe, T., Nakamura, S., Mashino, T.,
2013. Antioxidant activities of 5-hydroxyoxindole and its 3-
hydroxy-3-phenacyl derivatives: the suppression of lipid peroxida-
tion and intracellular oxidative stress. Bioorg. Med. Chem. 21,
7709–7714.evaluation of 5-(2-(4-(substituted benzo[d]isoxazol-3-yl) piperazin-1-yl)acetyl)in-
s novel anti-tubercular agents. Arabian Journal of Chemistry (2015), http://
